Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.70 |
| ▸ | CTSL | P07711 | 4/20 | 0.70 |
| ▸ | CTSB | P07858 | 4/20 | 0.70 |
| ▸ | KYNU | Q16719 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 7/20 | 0.54 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16346611 | 0.90 | KYNU (0.59) | CTSSCTSLCTSBKYNUALDH1A1 | |
| SCHEMBL3824323 | 0.90 | CTSS (0.71) | CTSSCTSLCTSBKYNUALDH1A1 | |
| SCHEMBL2400100 | 0.90 | CTSS (0.71) | CTSSCTSLCTSBKYNUALDH1A1 | |
| SCHEMBL2400096 | 0.90 | CTSS (0.71) | CTSSCTSLCTSBKYNUALDH1A1 | |
| SCHEMBL371131 | 0.89 | KYNU (0.58) | CTSSCTSLCTSBKYNUALDH1A1 | |
| SCHEMBL1069173 | 0.89 | KYNU (0.58) | CTSSCTSLCTSBKYNUALDH1A1 | |
| SCHEMBL3292733 | 0.89 | CTSS (0.70) | CTSSCTSLCTSBKYNUALDH1A1 | |
| SCHEMBL5189293 | 0.88 | KYNU (0.57) | CTSSCTSLCTSBKYNUALDH1A1 | |
| SCHEMBL952205 | 0.88 | KYNU (0.59) | CTSSCTSLCTSBKYNUALDH1A1 | |
| SCHEMBL952204 | 0.88 | KYNU (0.59) | CTSSCTSLCTSBKYNUALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718611-B2 | Cyclic nonapeptide amides | AICURIS GMBH & CO. KG (DE) | 2010-05-18 | — | — | US | disclosed |
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AICURIS GMBH & CO. KG (DE) | 2008-03-20 | — | — | US | disclosed |
| CN-101107265-A | Cyclic nonapeptide amides | AICURIS GMBH & CO KG (DE) | 2008-01-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AAAS, PGLS, NRDC | CTSS 339/4885CTSL 360/4885CTSB 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.